Handa Pharmaceuticals, Inc. (TPEX: 6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
57.70
-0.90 (-1.54%)
Nov 21, 2024, 2:59 PM CST
-63.13%
Market Cap 8.15B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 141.20M
EPS (ttm) 3.24
PE Ratio 17.80
Forward PE 3.61
Dividend 1.00 (1.71%)
Ex-Dividend Date n/a
Volume 193,153
Open 58.70
Previous Close 58.60
Day's Range 57.20 - 59.20
52-Week Range 57.00 - 206.00
Beta 1.31
Analysts n/a
Price Target n/a
Earnings Date Dec 26, 2024

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-0... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.